Free Newsletter
ALSO NOTED: Korea fines pharma firms for kickbacks; Medco boosts profits 16 percent;
> Ten Korean drug makers were fined $22 million for illegal rebates to hospitals and wholesalers. Report
> Pharmacy-benefits giant Medco Health Solutions posted a 16 percent hike in third-quarter profits and boosted its year-end earnings outlook again. Report
> Shire boasted a 41 percent increase in sales for the quarter, to $543 million, and raised its prediction for 2007 revenue growth to 30 percent from 25 percent. Release
> Shire also appointed MedImmune CEO David Mott as non-executive director; Mott also is executive vice president of AstraZeneca, which owns MedImmune. Report
> Drugs distributor Amerisource Bergen saw fourth-quarter profits fall 28 percent because of a big writedown on vaccine inventories. Report
> Smith & Nephew reported a 16 percent increase in adjusted earnings per share on a 24 percent increase in revenue to $845 million. Report
> A revolution in genomics and molecular biology has spurred a burst of new development activity in the vaccines business. Report
And Finally... Nematode worms treated with lithium live 46 percent longer. Would humans? Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: